To determine the biological consequence of the AR/lncTCFL5-2/YBX1/SOX2 signaling axis under hypoxia in the RCC progression, we focused on the chemotherapy resistance, since early studies indicated that CSCs formation is often negatively correlated with therapy resistance, such as resistance to Sunitinib, the first-line treatment of RCC [15, 16]. This evidence concerns the gene YBX1 and renal cell carcinoma.